Where is Systemic Primary Carnitine Deficiency Most Common?

Systemic Primary Carnitine Deficiency (SPCD) is a globally rare genetic condition, but its prevalence varies significantly depending on where you are in the world. Globally, the condition affects approximately 1 in 30,000 to 1 in 35,000 newborns ^[1]. However, because SPCD is an autosomal recessive disorder (meaning you must inherit two copies of the mutated gene, one from each parent, to develop the condition) caused by genetic mutations in the SLC22A5 gene, certain populations have a much higher rate of the disease due to a phenomenon known as the founder effect ^[2][3].

A founder effect occurs when a new population is established by a very small number of individuals from a larger population. If one of those original “founders” carries a rare genetic mutation, that mutation can become unusually common in the new, relatively isolated population over generations ^[3].

High Prevalence in the Faroe Islands and Japan

The most striking example of this founder effect is seen in the Faroe Islands. While the global prevalence is roughly 1 in 30,000 ^[1], the prevalence in the Faroe Islands is exceptionally high, estimated at 1 in 300 ^[4]. Because a specific mutation in the SLC22A5 gene was introduced and propagated within this isolated population, the carrier frequency among the Faroese is dramatically higher than anywhere else in the world ^[3]. Prior to the implementation of widespread screening, this high prevalence was associated with an increased risk of sudden unexplained death in young individuals in the region ^[3], though this is now highly preventable with proper screening and treatment ^[5].

Japan also sees a relatively higher incidence rate of SPCD compared to many Western countries, driven by regional genetic variations ^[1]. When comparing these regions to the United States, the differences are stark. The incidence of SPCD in the United States is much lower, reflecting a broader, more genetically diverse population without a single predominant founder mutation ^[1]. Overall, population-specific prevalence estimates around the world can range anywhere from 1 in 20,000 to as rare as 1 in 450,000 depending on ethnicity ^[1].

The Impact of Screening and Early Detection

Because the prevalence can be surprisingly high in certain groups, newborn screening (NBS) (a public health program that tests infants shortly after birth for a list of conditions) plays a critical role in detecting SPCD early ^[5]. NBS identifies asymptomatic infants before severe complications like heart issues (such as cardiomyopathy, a disease of the heart muscle that makes it harder to pump blood) or sudden metabolic crises occur ^[6].

While newborn screening catches most cases, older individuals can also be diagnosed later in life, often when investigating symptoms like muscle weakness or after a family member is diagnosed ^[7]. Because of the high prevalence in specific populations, adult carrier screening or genetic counseling may also be recommended for prospective parents of Faroese or Japanese descent.

When identified early, whether in infancy or adulthood, patients can be treated with lifelong L-carnitine supplementation, which is highly effective at preventing or reversing these serious symptoms ^[8][9]. Even if you live in a region with a very low incidence, such as the United States, screening ensures that those rare cases are caught and managed promptly ^[5].